These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26548104)

  • 1. [Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].
    Elovaara I; Soilu-Hänninen M; Kuusisto H; Martola J; Tienari P; Färkkilä M; Remes AM
    Duodecim; 2015; 131(17):1571-80. PubMed ID: 26548104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
    J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INNOVATIVE THERAPIES REDEFINE TREATMENT GOALS IN MULTIPLE SCLEROSIS.
    Lazibat I; Šamija RK; Rotim K
    Acta Clin Croat; 2016 Mar; 55(1):125-33. PubMed ID: 27333728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
    Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multiple sclerosis: beyong first line therapies].
    Schluep M; Du Pasquier R
    Rev Med Suisse; 2012 May; 8(339):946-9. PubMed ID: 22675826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
    Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
    Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.
    Heath G; Airody A; Gale RP
    Drugs; 2017 Mar; 77(3):303-311. PubMed ID: 28181178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
    Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
    J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of immune modulating drugs for the treatment of multiple sclerosis.
    Al-Khamis FA
    Neurosciences (Riyadh); 2016 Jan; 21(1):4-9. PubMed ID: 26818160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study.
    Zivadinov R; Khan N; Medin J; Christoffersen P; Price J; Korn JR; Bonzani I; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B
    J Neuroimaging; 2017 May; 27(3):339-347. PubMed ID: 27918139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.